-
Entrada to initiate an increased dose cohort in their Duchenne exon-44 skipping program
As an early funder of Entrada Therapeutics, CureDuchenne is pleased to share that after the
-
1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247
Dosing has begun in a Phase 2 clinical trial testing the oral therapy SAT-3247 in








